Regarding the therapeutic opportunities related to MMP inhibition in PD, in vivo studies have shown the expression of TIMP-1 and TIMP-2 in the substantia nigra of postmortem brain samples of PD patients [39]. This evidence concerns the gene TIMP1 and Parkinson disease.